On the morning of March 9, 2023, the 68th Standing Committee Meeting of the Twelfth Zhangjiagang Municipal Party Committee and the Special Research Conference on Hi-tech Zone (Tangqiao Township) and Phoenix Township was grandly held.
Before the meeting, the leading group of the Standing Committee of Zhangjiagang Municipal Party Committee inspected Womei Bio's production base in Fenghuang Town, Zhangjiagang, and Dr. Teng Xiaonuo, Chairman of the Board of Directors of the Group, accompanied them throughout the meeting.
The leading group of Zhangjiagang Municipal Party Committee Standing Committee and other inspectors visited Womei Bio's bioreactor display line, learned in detail about the whole process from the production line to the powder medium process, and carefully inquired about Womei Bio's construction and the results achieved. Dr. Teng Xiaonuo made a detailed introduction for the leaders, during which they praised the modern production technology of Womei production base. During the whole visit, the leadership team of Zhangjiagang Municipal Party Committee constantly asked about the difficulties and problems encountered in the project construction and company operation, gave guiding opinions, and emphasized the need to give full play to the core competitiveness of the enterprise, continue to innovate, and continue to strengthen technical research and development with the support of Zhangjiagang Municipal Government's various encouraging measures for the enterprise, and strive to master more core and cutting-edge technologies, and constantly realize key processes and new breakthroughs to further enhance the competitiveness of the enterprise. New breakthroughs to further enhance the competitiveness of enterprises to create high-quality, high-standard products.
As a leading one-stop solution provider of biopharmaceuticals in China, Suzhou Womei Biology CO,.Ltd has always insisted on technological innovation, continuously increased investment in R&D, and is committed to becoming a leading integrated service provider of complete solutions in the field of biopharmaceuticals in China. Now we have completed the layout of production lines including personalized culture media, bioreactors, immunoadjuvants, biochemical reagents, etc., and have industry-leading technology systems in the fields of antibody therapy, vaccine development, cellular bioreactor applications, etc. We are the core supplier of upstream and downstream biotechnology processes, as well as providing formulations, process optimization, process validation, technical support and ancillary services for the biopharmaceutical industry.
Womei Bio currently has two own factories in Zhangjiagang and Nantong. Womei Bio's subsidiary, Womei Bio, together with the State Key Laboratory of Bioreactors of East China University of Science and Technology (ECTU), jointly founded the "ECTU-Womei Bio-reactor Process Control and Intelligent Manufacturing Joint Technology Innovation Transfer Center", which is a joint venture between ECTU and the State Key Laboratory of Bioreactors of East China University of Science and Technology. VTech Bioreactor Process Control and Intelligent Manufacturing Joint Technology Innovation Transfer Center". The technology innovation center will give full play to the leading advantages of the State Key Laboratory of Reactors in process control and intelligent manufacturing of animal cell reactors, focusing on the laboratory scale to 20,000 liters or more of ultra-large-scale production-scale bioreactors, deeply cultivating the key technologies for digital transformation of the modern biomedical industry, and accelerating the development of process technology, utilizing large-scale bioreactor suspension technology to cultivate cells, improve the vaccine potency and stability of batch-to-batch quality, reduce contamination, and improve the quality and stability of vaccines. stable batch-to-batch quality, reduce contamination and ensure production.
At present, Zhangjiagang No. 1 production base has been completed and put into use, No. 2 production base and Wotis factory is stepping up the construction, after the completion of the construction, able to achieve the GMP standard, a single batch of more than 100,000 liters of low-temperature needle milling powder process capacity building, the total production capacity of more than 50 million liters. It has built a leading industrial bioreactor manufacturing base in China, which can realize the production requirements of 3,000-20,000 liters of bioreactors.
